-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
News on April 14, 2021 /bioon.
com" target="_blank">/ --Galectin Therapeutics is a leader in the development of innovative drugs targeting galectin protein, and is committed to applying its leadership in galectin science and drug development to the creation of new therapies to improve chronic diseases Liver disease, skin disease, cancer patient's life.
bioon.com" target="_blank">/ --Galectin Therapeutics is a leader in the development of innovative drugs targeting galectin protein, and is committed to applying its leadership in galectin science and drug development to the creation of new therapies to improve chronic diseases Liver disease, skin disease, cancer patient's life.
com" target="_blank">
Recently, the company announced that a study published in the peer-reviewed journal "Journal for ImmunoTherapy of Cancer," (JITC), provides further clinical evidence to show that in advanced metastatic bioon.
com/course_video/ge-tian831892.
html">melanoma (MM) and In patients with head and neck squamous cell carcinoma (HNSCC), the powerful galectin-3 (gal-3, Gal-3) inhibitor belapectin and the PD-1 inhibitor Keytruda (common name: pembrolizumab) , Pembrolizumab) combined use, can significantly enhance bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor response to immunotherapy.
bioon.com/course_video/ge-tian831892.
html">melanoma (MM) and In patients with head and neck squamous cell carcinoma (HNSCC), the powerful galectin-3 (gal-3, Gal-3) inhibitor belapectin and the PD-1 inhibitor Keytruda (common name: pembrolizumab) , Pembrolizumab) combined use, can significantly enhance bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor response to immunotherapy.
com/course_video/ge-tian831892.
html">Melanoma bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">Tumor
belapectin (formerly GR-MD-02) is a lead drug candidate of Galectin Therapeutics.
This is a carbohydrate-based drug that inhibits galectin-3 (Gal-3), which is directly involved in a variety of inflammations , fibrosis, malignant bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor .
Previously, the US bioon.
com/fda/" target="_blank">FDA has granted belapectin Fast Track Status (FTD).
Currently, belapectin is developing projects including: fibrosis, cancer immunotherapy (combination therapy), and plaque psoriasis.
bioon. This is a carbohydrate-based drug that inhibits galectin-3 (Gal-3), which is directly involved in a variety of inflammations , fibrosis, malignant bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor .
Previously, the US bioon.
com/fda/" target="_blank">FDA has granted belapectin Fast Track Status (FTD).
Currently, belapectin is developing projects including: fibrosis, cancer immunotherapy (combination therapy), and plaque psoriasis.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">Oncology bioon.
com/fda/" target="_blank">FDA
Galectin-3 (Gal-3) is produced by tumor cells and macrophages, and has a variety of effects, including: (1) promoting bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor cell angiogenesis and metastasis ; (2) promoting macrophage M2 polarization, Increase chemotaxis to recruit more macrophages and enhance Gal-3 secretion ; (3) Reduce T cell receptor signals and promote T bioon.
com/tags/%E7%BB%86%E8%83%9E%E5%87%8B%E4%BA%A1/">cell apoptosis (cell death), thereby blocking the immune effect on bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor cells.
bioon. com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor cell angiogenesis and metastasis ; (2) promoting macrophage M2 polarization, Increase chemotaxis to recruit more macrophages and enhance Gal-3 secretion ; (3) Reduce T cell receptor signals and promote T bioon.
com/tags/%E7%BB%86%E8%83%9E%E5%87%8B%E4%BA%A1/">cell apoptosis (cell death), thereby blocking the immune effect on bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor cells.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">Tumor ; (2) Promote the polarization of macrophages M2, increase chemotaxis to recruit more macrophages, and enhance Gal-3 secretion ; (3) Reduce T cell receptor signals and promote T bioon.
com/tags/%E7%BB%86%E8%83%9E%E5%87%8B%E4%BA%A1/">cell apoptosis (cell death) ), thereby blocking the immune effect on bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor cells.
bioon.
com/tags/%E7%BB%86%E8%83%9E%E5%87%8B%E4%BA%A1/">Apoptotic bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor
Due to the multiple effects of Gal-3 on the immune system, Gal-3 inhibitors may have synergistic effects with other immunotherapies.
Preclinical studies have shown that the combination of belapectin and the following drugs have a positive effect on many types of bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumors , including checkpoint inhibitors (anti-CTLA-4 therapy [Yervoy] and anti-PD-1 therapy [Keytruda]) and T cell agonists ( Anti-OX40 therapy, under development).
bioon. Preclinical studies have shown that the combination of belapectin and the following drugs have a positive effect on many types of bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumors , including checkpoint inhibitors (anti-CTLA-4 therapy [Yervoy] and anti-PD-1 therapy [Keytruda]) and T cell agonists ( Anti-OX40 therapy, under development).
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">Tumor
belapectin (GR-MD-02) can enhance the anti-tumor activity of cancer immunotherapy
bmj.
com/content/9/4/e002371" target="_blank">Thesis titled " bmj.
com/content/9/4/e002371" target="_blank">Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor " (doi (:10.
1136/jitc-2021-002371) describes the results of an ongoing phase 1 clinical study, which is Galectin Therapeutics and Providence Cancer Institute (PCI) in Portland, Oregon, USA Cooperate.
bmj. com/content/9/4/e002371" target="_blank">Thesis titled " bmj.
com/content/9/4/e002371" target="_blank">Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor " (doi (:10.
1136/jitc-2021-002371) describes the results of an ongoing phase 1 clinical study, which is Galectin Therapeutics and Providence Cancer Institute (PCI) in Portland, Oregon, USA Cooperate.
com/content/9/4/e002371" target="_blank">Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor
A recently published positive preclinical study showed that the inhibitory effect of galectin-3 combined with anti-OX40 monoclonal antibody agonists reprograms the tumor microenvironment and promotes anti-tumor activity.
The Phase I study published in JITC this time validated this clinical hypothesis that the use of belapectin to block galectin-3 combined with Keytruda can enhance bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor response in patients with advanced MM or HNSCC .
bioon. The Phase I study published in JITC this time validated this clinical hypothesis that the use of belapectin to block galectin-3 combined with Keytruda can enhance bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor response in patients with advanced MM or HNSCC .
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">Tumor
In this study, receiving belapectin and Keytruda combination therapy, objective remission was observed in 50% of MM (7/14) patients and 33% of HNSCC (2/6) patients .
This compares favorably with the published remission rate of Keytruda monotherapy.
The authors point out that the combination is associated with fewer immune-mediated adverse events than Keytruda alone.
In addition, the analysis of the patient's tumor tissue showed that compared with non-responders, the responders had fewer monocyte-derived suppressor cells and increased effector memory T cell activation.
In addition, increased baseline expression of galectin-3 positive bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor cells correlated with clinical response.
Objective bioon. This compares favorably with the published remission rate of Keytruda monotherapy.
The authors point out that the combination is associated with fewer immune-mediated adverse events than Keytruda alone.
In addition, the analysis of the patient's tumor tissue showed that compared with non-responders, the responders had fewer monocyte-derived suppressor cells and increased effector memory T cell activation.
In addition, increased baseline expression of galectin-3 positive bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor cells correlated with clinical response.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor remission was observed in 50% of MM (7/14) patients and 33% of HNSCC (2/6) patientsbioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">
jpg" target="_blank">
jpg" target="_blank">Clinical efficacy of belapectin and Keytruda combination therapy
The first author of the article and PCI researcher Brendan Curti, MD, said: “Immunotherapy is a major breakthrough in the treatment of many cancers, but tumor-induced immunosuppression can lead to treatment resistance.
Galectin-3 is one of the bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor- induced immunosuppression.
Important driving factor.
This clinical study proves that adding the galectin-3 inhibitor belapectin to PD-1 inhibitors can benefit cancer patients.
bioon. Galectin-3 is one of the bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor- induced immunosuppression.
Important driving factor.
This clinical study proves that adding the galectin-3 inhibitor belapectin to PD-1 inhibitors can benefit cancer patients.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">Tumor
"
Pol F.
Boudes, MD, Chief Medical Officer of Galectin Therapeutics, said: "The results of the analysis of patient tumor tissues are consistent with previously published preclinical data on belapectin, and confirm the ability of belapectin to regulate the tumor microenvironment to promote anti- bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor activity.
The potential to improve the tolerability and safety of immunotherapy is also very exciting.
These proof-of-concept clinical data provide a strong theoretical basis for conducting a randomized placebo-controlled phase 2 bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">clinical trial to evaluate these cancer patients In the population, the efficacy and safety of belapectin combined with PD-1 inhibitors compared with PD-1 inhibitors alone.
We look forward to continuing the cooperation with PCI and expanding the cohort of this study with additional data that will be published soon Full of expectation.
" ()
bioon. Boudes, MD, Chief Medical Officer of Galectin Therapeutics, said: "The results of the analysis of patient tumor tissues are consistent with previously published preclinical data on belapectin, and confirm the ability of belapectin to regulate the tumor microenvironment to promote anti- bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor activity.
The potential to improve the tolerability and safety of immunotherapy is also very exciting.
These proof-of-concept clinical data provide a strong theoretical basis for conducting a randomized placebo-controlled phase 2 bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">clinical trial to evaluate these cancer patients In the population, the efficacy and safety of belapectin combined with PD-1 inhibitors compared with PD-1 inhibitors alone.
We look forward to continuing the cooperation with PCI and expanding the cohort of this study with additional data that will be published soon Full of expectation.
" ()
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">Oncology bioon.
com/course_video/lin-chuang-shi-yan-de-feng-xian-jian-kong239833.
html">clinical trials ()
Original Source: Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics' Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
